#JPM24: Ultragenyx nears $50M Series A for its Alzheimer’s gene therapy spinout

SAN FRANCISCO — Ultragenyx, the commercial-stage California biotech working on ultra-rare diseases, is finishing up a $50 million Series A fundraise for its Alzheimer’s gene therapy spinout, named Amlogenyx, CEO Emil Kakkis told Endpoints News.

“We have a lead investor signed on, and we have several investors who are on…
Click here to view original post

Advertisement — Advertise with Biotech Networks